Collaboration to develop stem cell therapies for COVID-19 and future pandemic diseases. Avacta has announced an expansion of its collaboratin with Daewoong Pharmaceutical Co and AffyXell Therapeutics are to to develop stem cell treatments incorporating Avacta’s neutralising Affimer therapy for the treatment of seriously ill patients with COVID-19… Read More
The experimental drug has shown promise in early-stage clinical trials conducted in Singapore, by Anne Trafton, MIT News Office. Yellow fever, a haemorrhagic disease that is common in South America and sub-Saharan Africa, infects about 200,000 people per year and causes an estimated 30,000 deaths. While there is… Read More
Stanford chemists have developed a new tool that shuttles unwanted cell surface proteins to their deaths, by Rebecca McClellan When scientists find a potentially dangerous protein on a cell, they might imagine shrinking themselves down to become tiny surgeons, cutting out just the problematic molecule and leaving the… Read More
The COVID-19 antiviral race: we're all in this together By Uduak Grace Thomas In response to the COVID-19 pandemic, international scientists from academia and industry have pooled their expertise and resources to identify candidate compounds that inhibit the activity of the SARS-CoV-2 main protease, in order to develop a clinically… Read More
Ligandal has announced positive results of lab studies that indicate the likelihood of the synthetic peptide, SARS-BLOCK, becoming an effective combination treatment and vaccine to COVID-19. The experiments, in conjunction with the Stroud Lab, University of California San Francisco, demonstrate SARS-BLOCK halts infection of SARS-CoV-2. In addition to… Read More
Evotec has partnered with partnership with the biotech company Resolute Therapeutics to combat infectious diseases and antimicrobial resistance. The partnership aims to develop a broad-spectrum antibiotic with a new mode of action compared with antibiotics currently on the market and will receive substantial funding from CARB-X (Combating Antibiotic-Resistant… Read More
Avacta and Liverpool School of Tropical Medicine collaborate to clinically validate saliva-based rapid coronavirus test being developed with Cytiva. Avacta has entered into a collaboration with the Liverpool School of Tropical Medicine (LSTM) to clinically validate the rapid, saliva-based coronavirus antigen test that Avacta is developing with Cytiva. Read More
By Richard Gray The recent outbreak of COVID-19 has highlighted the need for fast and efficient development and production of vaccines for a whole gamut of pathogens, old and new. Microfluidics technologies can be used to accelerate the vaccine development process in a number of ways, not least in the… Read More
It is said to be ideal for cell and gene therapy and COVID-19 research. BioStore IIIv is also said to provide improved thermal stability for stored materials, risk mitigation advantages and processes which are documented and repeatable. BioStore IIIv operates like a vending machine. After a secure login… Read More
AI-powered platform allows users to select top-performing investigators worldwide and save up to $2.4m per trial on non-performing sites. Phesi, a data-driven provider of clinical development analytics products and solutions, has added a new country selection functionality to ClinSite. This AI platform provides investigator site intelligence to clients,… Read More
Avacta has appointed BBI Solutions to manufacture the saliva-based rapid SARS-CoV-2 antigen test that is being developed with Cytiva. BBI Solutions is a leading global developer and manufacturer of raw materials and finished test products for the in-vitro diagnostics market, with manufacturing sites in five different countries, spanning… Read More
The BIA (UK Bioindustry Association) is helping the UK Government (Office for Life Sciences) to raise awareness of an urgent call out to the life sciences sector to help increase the supply of antigen testing kits for COVID-19. Following a press statement on March 26, the… Read More
The Opencorona consortium has awarded €3 million funding by Horizon 2020 to support emergency research and development against the COVID-19 outbreak. Cobra Biologics (Cobra), an international CDMO for biologics and pharmaceuticals, and the Karolinska Institutet (KI), one of the world’s leading medical universities, announced on March 30, they… Read More
Miltenyi Biotec has launched its SARS-CoV-2 PepTivator Peptide Pools, a new addition to its PepTivator Portfolio specifically developed to help researchers currently investigating COVID-19 Based on decades worth of experience in developing products for virus-specific T cell research, SARS-CoV-2 PepTivator Peptide Pools work by stimulating T cells specific… Read More
The UK’s Department of Health and Social Care has published a letter setting out its government’s plan and requests of industry and the wider supply chain ahead of the end of the Brexit transition period. This aims to help ensure the continuity of supply of medical goods into… Read More
The vaccine is currently being evaluated in Phase 3 clinical testing. The investigational vaccine known as mRNA-1273 protected mice from infection with SARS-CoV-2, the virus that causes COVID-19, according to research published today in Nature. Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the… Read More
